Ascentage Pharma gets China NMPA nod to start registrational phase III studies of APG─2449 to for treat patients with ...
Ascentage Pharma, a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, announced that APG-2449, a FAK/ALK/ROS1 tyrosine kinase …